Laminin 221 fragment is suitable for the differentiation of human induced pluripotent stem cells into brain microvascular endothelial-like cells with robust barrier integrity.
Animals
Biocompatible Materials
Blood-Brain Barrier
/ cytology
Cell Differentiation
/ physiology
Cell Line
Cells, Cultured
Collagen
Cytological Techniques
Drug Combinations
Endothelial Cells
/ cytology
Humans
Induced Pluripotent Stem Cells
/ cytology
Laminin
Mice
Microvessels
/ cytology
Proteoglycans
Blood–brain barrier
Brain microvascular endothelial cell
Differentiation
Human induced pluripotent stem cell
Laminin 221
Journal
Fluids and barriers of the CNS
ISSN: 2045-8118
Titre abrégé: Fluids Barriers CNS
Pays: England
ID NLM: 101553157
Informations de publication
Date de publication:
30 Mar 2020
30 Mar 2020
Historique:
received:
07
11
2019
accepted:
17
03
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
1
12
2020
Statut:
epublish
Résumé
In vitro blood-brain barrier (BBB) models using human induced pluripotent stem (iPS) cell-derived brain microvascular endothelial-like cells (iBMELCs) have been developed to predict the BBB permeability of drug candidates. For the differentiation of iBMELCs, Matrigel, which is a gelatinous protein mixture, is often used as a coating substrate. However, the components of Matrigel can vary among lots, as it is obtained from mouse sarcoma cells with the use of special technics and also contains various basement membranes. Therefore, fully defined substrates as substitutes for Matrigel are needed for a stable supply of iBMELCs with less variation among lots. iBMELCs were differentiated from human iPS cells on several matrices. The barrier integrity of iBMELCs was evaluated based on transendothelial electrical resistance (TEER) values and permeability of fluorescein isothiocyanate-dextran 4 kDa (FD4) and Lucifer yellow (LY). Characterization of iBMELCs was conducted by RT-qPCR and immunofluorescence analysis. Functions of efflux transporters were defined by intracellular accumulation of the substrates in the wells of multiwell plates. iBMELCs differentiated on laminin 221 fragment (LN221F-iBMELCs) had higher TEER values and lower permeability of LY and FD4 as compared with iBMELCs differentiated on Matrigel (Matrigel-iBMELCs). Besides, the gene and protein expression levels of brain microvascular endothelial cells (BMEC)-related markers were similar between LN221F-iBMELCs and Matrigel-iBMELCs. Moreover, both Matrigel- and LN221F-iBMELCs had functions of P-glycoprotein and breast cancer resistance protein, which are essential efflux transporters for barrier functions of the BBB. The fully defined substrate LN221F presents as an optimal coating matrix for differentiation of iBMELCs. The LN221F-iBMELCs had more robust barrier function for a longer period than Matrigel-iBMELCs with characteristics of BMECs. This finding will contribute the establishment of an iBMELC supply system for pharmacokinetic and pathological models of the BBB.
Sections du résumé
BACKGROUND
BACKGROUND
In vitro blood-brain barrier (BBB) models using human induced pluripotent stem (iPS) cell-derived brain microvascular endothelial-like cells (iBMELCs) have been developed to predict the BBB permeability of drug candidates. For the differentiation of iBMELCs, Matrigel, which is a gelatinous protein mixture, is often used as a coating substrate. However, the components of Matrigel can vary among lots, as it is obtained from mouse sarcoma cells with the use of special technics and also contains various basement membranes. Therefore, fully defined substrates as substitutes for Matrigel are needed for a stable supply of iBMELCs with less variation among lots.
METHODS
METHODS
iBMELCs were differentiated from human iPS cells on several matrices. The barrier integrity of iBMELCs was evaluated based on transendothelial electrical resistance (TEER) values and permeability of fluorescein isothiocyanate-dextran 4 kDa (FD4) and Lucifer yellow (LY). Characterization of iBMELCs was conducted by RT-qPCR and immunofluorescence analysis. Functions of efflux transporters were defined by intracellular accumulation of the substrates in the wells of multiwell plates.
RESULTS
RESULTS
iBMELCs differentiated on laminin 221 fragment (LN221F-iBMELCs) had higher TEER values and lower permeability of LY and FD4 as compared with iBMELCs differentiated on Matrigel (Matrigel-iBMELCs). Besides, the gene and protein expression levels of brain microvascular endothelial cells (BMEC)-related markers were similar between LN221F-iBMELCs and Matrigel-iBMELCs. Moreover, both Matrigel- and LN221F-iBMELCs had functions of P-glycoprotein and breast cancer resistance protein, which are essential efflux transporters for barrier functions of the BBB.
CONCLUSION
CONCLUSIONS
The fully defined substrate LN221F presents as an optimal coating matrix for differentiation of iBMELCs. The LN221F-iBMELCs had more robust barrier function for a longer period than Matrigel-iBMELCs with characteristics of BMECs. This finding will contribute the establishment of an iBMELC supply system for pharmacokinetic and pathological models of the BBB.
Identifiants
pubmed: 32228708
doi: 10.1186/s12987-020-00186-4
pii: 10.1186/s12987-020-00186-4
pmc: PMC7106710
doi:
Substances chimiques
Biocompatible Materials
0
Drug Combinations
0
Laminin
0
Proteoglycans
0
matrigel
119978-18-6
Collagen
9007-34-5
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP19be0304322
Organisme : Japan Society for the Promotion of Science
ID : JP17K08422
Références
Drug Metab Dispos. 2009 Mar;37(3):635-43
pubmed: 19047468
Biochim Biophys Acta. 2009 Apr;1788(4):842-57
pubmed: 19061857
Cell Rep. 2019 Mar 19;26(12):3231-3245.e9
pubmed: 30893597
Cell Mol Life Sci. 2010 Sep;67(17):2879-95
pubmed: 20428923
Fluids Barriers CNS. 2017 Apr 13;14(1):9
pubmed: 28407791
Stem Cell Reports. 2019 Jun 11;12(6):1380-1388
pubmed: 31189096
Stem Cells. 2018 Dec;36(12):1816-1827
pubmed: 30171748
Stem Cell Reports. 2017 Apr 11;8(4):894-906
pubmed: 28344002
Sci Rep. 2014 Feb 24;4:4160
pubmed: 24561821
PLoS One. 2017 Oct 23;12(10):e0187017
pubmed: 29059256
FASEB J. 2005 Nov;19(13):1872-4
pubmed: 16141364
PLoS One. 2011 Feb 03;6(2):e16767
pubmed: 21304816
Fluids Barriers CNS. 2016 Apr 12;13:6
pubmed: 27068644
J Cereb Blood Flow Metab. 2016 May;36(5):862-90
pubmed: 26868179
Biochem Biophys Res Commun. 2019 Aug 6;515(4):672-678
pubmed: 31178142
Dev Neurobiol. 2011 Nov;71(11):1018-39
pubmed: 21780303
J Neurosci. 2014 Nov 12;34(46):15260-80
pubmed: 25392494
Fluids Barriers CNS. 2015 May 21;12:13
pubmed: 25994964
Nat Commun. 2019 Jun 13;10(1):2621
pubmed: 31197168
J Pharmacol Exp Ther. 2016 Aug;358(2):294-305
pubmed: 27194478
Nat Biotechnol. 2012 Aug;30(8):783-91
pubmed: 22729031
Bio Protoc. 2017 May 20;7(10):
pubmed: 28603749